세계의 제네릭 의약품 시장 (2023~2030) : 단순 제네릭, 특수 제네릭, 바이오시밀러

■ 영문 제목 : Generic Pharmaceuticals Market Size, Share & Trends Analysis Report By Type (Simple Generics, Specialty Generics, Biosimilars), By Route Of Administration, By Product, By Application, By Distribution Channel, By Region And Segment Forecasts, 2023 - 2030

Grand View Research가 발행한 조사보고서이며, 코드는 GRV23MR095 입니다.■ 상품코드 : GRV23MR095
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 2월
■ 페이지수 : 220
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의약품
■ 판매가격 / 옵션 (부가세 10% 별도)
Single User (1인 열람용)USD5,950 ⇒환산￦8,330,000견적의뢰/주문/질문
Multi User (5인 열람용)USD6,950 ⇒환산￦9,730,000견적의뢰/주문/질문
Global/corporate License (기업 열람용)USD8,950 ⇒환산￦12,530,000견적의뢰/구입/질문
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 제네릭 의약품 시장 규모가 2023년부터 2030년 사이에 CAGR 8.3% 증가하여, 2030년에는 6,829억 달러에 이를 것으로 예측하고 있습니다. 본 자료는 세계의 제네릭 의약품 시장을 조사대상으로 하여, 조사 방법 및 범위, 개요, 시장 변동/동향/범위, 종류별 (단순 제네릭, 특수 제네릭, 바이오시밀러) 분석, 용도별 (중추 신경계 질환, 호흡기 질환, 호르몬 관련 질환, 소화기 질환, 기타) 분석, 제품별 (저분자, 고분자) 분석, 투여 경로별 (경구, 주사, 흡입, 기타) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동, 아프리카) 분석, 경쟁 분석 등의 내용을 게재하고 있습니다. 또한 본 리포트는 Teva Pharmaceutical Industries Ltd, Viatris Inc., Sun Pharmaceutical Industries Ltd., LUPIN, Novartis AG, Allergan, AstraZeneca, Sawai Pharmaceutical Co., Ltd., Hikma Pharmaceuticals PLC, Reddy's Laboratories Ltd., Cipla Inc., Sanofi, Aurobindo Pharma, Endo International plc 와 같은 기업 정보를 포함하고 있습니다.
・조사 방법 및 범위
・개요
・시장 변동/동향/범위
・세계의 제네릭 의약품 시장 규모 : 종류별
- 단순 제네릭의 시장 규모
- 특수 제네릭의 시장 규모
- 바이오시밀러의 시장 규모
・세계의 제네릭 의약품 시장 규모 : 용도별
- 중추 신경계 질환에 사용되는 제네릭 의약품의 시장 규모
- 호흡기 질환에 사용되는 제네릭 의약품의 시장 규모
- 호르몬 관련 질환에 사용되는 제네릭 의약품의 시장 규모
- 소화기 질환에 사용되는 제네릭 의약품의 시장 규모
- 기타 용도에 사용되는 제네릭 의약품의 시장 규모
・세계의 제네릭 의약품 시장 규모 : 제품별
- 저분자 제네릭 의약품의 시장 규모
- 고분자 제네릭 의약품의 시장 규모
・세계의 제네릭 의약품 시장 규모 : 투여 경로별
- 경구용 제네릭 의약품의 시장 규모
- 주사용 제네릭 의약품의 시장 규모
- 흡입용 제네릭 의약품의 시장 규모
- 기타 제네릭 의약품의 시장 규모
・세계의 제네릭 의약품 시장 규모 : 지역별
- 북미의 제네릭 의약품 시장 규모
- 유럽의 제네릭 의약품 시장 규모
- 아시아 태평양의 제네릭 의약품 시장 규모
- 중남미의 제네릭 의약품 시장 규모
- 중동 및 아프리카의 제네릭 의약품 시장 규모
・경쟁 분석
■ 보고서 개요

Generic Pharmaceuticals Market Growth & Trends

The global generic pharmaceuticals market is expected to reach over USD 682.9 billion expanding at a CAGR of 8.3% from 2023 to 2030, according to a new study by Grand View Research Inc. The growth of the generic pharmaceuticals market is largely attributable to the expiry of product patents which clears the way for generic drugs and biosimilar manufacturers to launch products in the market. For instance, in July 2020, Teva Pharmaceutical Industries Ltd. entered into a joint venture with Takeda Pharmaceutical Company Limited aimed to manufacture and commercialize specialty assets, complex generic drugs, and other pipeline opportunities. This joint venture was anticipated to drive the generic pharmaceuticals market.

Furthermore, increasing government initiatives to promote generic drug products for reducing the overall healthcare expenditure on pharmaceuticals and the patent expiry of major products. For instance, the Therapeutic Goods Administration (TGA) Australia aims to offer affordable, efficient, high-quality, and accessible generic drugs to citizens for their treatment. In support of generic drugs, the TGA has been trying to reduce regulatory and reimbursement burdens such as changing the landscape of generic drugs and reducing barriers through international collaboration with manufacturers to launch their generic drugs in the market. Such initiatives of the Australian government open new avenues in the market.

In the U.S., every year millions of Americans use a generic drug for their treatment, hence, generic drugs remain the best bargain in the health care insurance programs, and given the recent enactment of healthcare reform legislation such as the introduction of the Patient Protection and Affordable Health Care Act. P.L. 111-148. Under this act, prescription drug coverage is mandated by the government as part of these new health insurance plans. The introduction of such policies may improve the quality and efficiency of healthcare, thereby, driving market growth.

The rising disease burden of infectious & non-infectious diseases coupled with the increasing geriatric population which is prone to chronic diseases such as diabetes, and hypertension, among others, may positively affect the market growth. According to an article published, in September 2022, around 17.9 million general population suffer from cardiovascular diseases (CVD) every year worldwide. Diseases including TB, diabetes, cardiovascular diseases, and HIV were among the major causes of death. The increasing incidence and prevalence of these diseases is expected to drive the market.

Generic Pharmaceuticals Market Report Highlights

• The small molecule segment by type held the largest share of 91.2% in 2022 and the large molecule segment is expected to grow at the fastest rate. The increasing approval and uptake of biosimilars is expected to drive the growth of the large molecule segment.

• Based on the route of administration, the injectable segment is the fastest-growing segment due to the rising approval for biosimilar drugs.

• By application, cardiovascular diseases dominated the market with a share of 18.27% in 2022, owing to the highest prescription rate of generic statins coupled with a high disease burden.

• Specialty generics are expected to grow moderately due to increasing investments and the focus of pharmaceutical companies to develop value-added products. In 2019, the U.S. FDA approved 110 complex generics.

• Based on distribution channel, the retail pharmacy segment dominated the market space in 2022. Retail pharmacy chains across the world are investing in advanced technologies and undertaking new initiatives to improve sales and attract more customers.

• North America held the majority share in 2022. Favorable government initiatives coupled with an evolving reimbursement landscape for pharmaceutical products support continual growth.

■ 보고서 목차

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Primary Research Analysis
1.11.1 Market scenario
1.11.2 Key KoL responses
1.12 Objectives
1.12.1 Objective 1:
1.12.2 Objective 2:
1.13 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Snapshoty
Chapter 3 Market Variables, Trends & Scope
3.1 Penetration and Growth Prospect Mapping
3.2 Regulatory Landscape
3.3 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.4 Porter’s Five Forces Analysis
3.5 User Perspective Analysis
3.6 Generic Pharmaceuticals Market Dynamics
3.6.1 Market Driver Analysis
3.6.1.1 Patent expiry of biologics and small molecules
3.6.1.2 Increasing ANDA approval and Generic Product Launches
3.6.1.3 Government initiatives to promote usage of generics
3.6.1.4 Increasing Disease Burden and Rising Geriatric Population
3.6.2 Market Restraint Analysis
3.6.2.1 Pricing Pressures
Chapter 4 Generic Pharmaceuticals Market – Segment Analysis, By Type, 2018 – 2030 (USD Billion)
4.1 Generic Pharmaceuticals Market: Type Movement Analysis
4.2 Simple Generics
4.2.1 Simple Generics Market Estimates and Forecast, 2018 – 2030 (USD Billion)
4.3 Specialty Generics
4.3.1 Specialty Generics Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
4.4 Biosimilars
4.4.1 Biosimilars Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
Chapter 5 Generic Pharmaceuticals Market – Segment Analysis, By Application, 2018 – 2030 (USD Billion)
5.1 Generic Pharmaceuticals Market: Application Movement Analysis
5.2 Central Nervous System Disorders
5.2.1 Central Nervous System Disorders Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.3 Respiratory Diseases
5.3.1 Respiratory Diseases Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.4 Hormones and Related Diseases
5.4.1 Hormones and Related Diseases Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.5 Gastrointestinal Diseases
5.5.1 Gastrointestinal Diseases Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.6 Cardiovascular Diseases
5.6.1 Cardiovascular Diseases Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.7 Infectious Diseases
5.7.1 Infectious Diseases Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.8 Cancer
5.8.1 Cancer Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.9 Diabetes
5.9.1 Diabetes Market Estimates and Forecast, 2018 – 2030 (USD Billion)
5.10 Others
5.10.1 Others Market Estimates and Forecast, 2018 – 2030 (USD Billion)
Chapter 6 Generic Pharmaceuticals Market – Segment Analysis, By Product, 2018 – 2030 (USD Billion)
6.1 Generic Pharmaceuticals Market: Product Movement Analysis
6.2 Small Molecule
6.2.1 Small Molecule Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
6.3 Large Molecule
6.3.1 Large molecule Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
Chapter 7 Generic Pharmaceuticals Market – Segment Analysis, By Route of Administration, 2018 – 2030 (USD Billion)
7.1 Generic Pharmaceuticals Market: Route of Administration Movement Analysis
7.2 Oral
7.2.1 Oral Market Estimates and Forecast, 2018 – 2030 (USD Billion)
7.3 Injectable
7.3.1 Injectable Market Estimates and Forecast, 2018 – 2030 (USD Billion)
7.4 Inhalable
7.4.1 Inhalable Market Estimates and Forecast, 2018 – 2030 (USD Billion)
7.5 Others
7.5.1 Others Market Estimates and Forecast, 2018 – 2030 (USD Billion)
Chapter 8 Generic Pharmaceuticals Market – Segment Analysis, By Distribution Channel, 2018 – 2030 (USD Billion)
8.1 Generic Pharmaceuticals Market: Distribution Channel Movement Analysis
8.2 Hospital Pharmacy
8.2.1 Hospital Pharmacy Market Estimates and Forecast, 2018 – 2030 (USD Billion)
8.3 Retail Pharmacy
8.3.1 Retail Pharmacy Market Estimates and Forecast, 2018 – 2030 (USD Billion)
8.4 Online Pharmacy
8.4.1 Online Pharmacy Market Estimates and Forecast, 2018 – 2030 (USD Billion)
Chapter 9 Generic Pharmaceuticals Market – Segment Analysis, By Region, 2018 – 2030 (USD Billion)
9.1 Generic Pharmaceuticals Market, Market Share by Region, 2022 & 2030
9.2 North America
9.2.1 SWOT Analysis
9.2.1.1 North America Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.2 U.S.
9.2.2.1 Key Country Dynamics
9.2.2.2 Target Disease Prevalence
9.2.2.3 Competitive Scenario
9.2.2.4 Regulatory Framework
9.2.2.5 Reimbursement Scenario
9.2.2.6 U.S. Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.3 Canada
9.2.3.1 Key Country Dynamics
9.2.3.2 Target Disease Prevalence
9.2.3.3 Competitive Scenario
9.2.3.4 Regulatory Framework
9.2.3.5 Reimbursement Scenario
9.2.3.6 Canada Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2 Europe
9.2.1 SWOT Analysis:
9.2.1.1 Europe Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.2 Germany
9.2.2.1 Key Country Dynamics
9.2.2.2 Target Disease Prevalence
9.2.2.3 Competitive Scenario
9.2.2.4 Regulatory Framework
9.2.2.5 Reimbursement Scenario
9.2.2.6 Germany Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.3 U.K.
9.2.3.1 Key Country Dynamics
9.2.3.2 Target Disease Prevalence
9.2.3.3 Competitive Scenario
9.2.3.4 Regulatory Framework
9.2.3.5 Reimbursement Scenario
9.2.3.6 UK Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.4 France
9.2.4.1 Key Country Dynamics
9.2.4.2 Target Disease Prevalence
9.2.4.3 Competitive Scenario
9.2.4.4 Regulatory Framework
9.2.4.5 Reimbursement Scenario
9.2.4.6 France Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.5 Italy
9.2.5.1 Key Country Dynamics
9.2.5.2 Target Disease Prevalence
9.2.5.3 Competitive Scenario
9.2.5.4 Regulatory Framework
9.2.5.5 Reimbursement Scenario
9.2.5.6 Italy Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.6 Spain
9.2.6.1 Key Country Dynamics
9.2.6.2 Target Disease Prevalence
9.2.6.3 Competitive Scenario
9.2.6.4 Regulatory Framework
9.2.6.5 Reimbursement Scenario
9.2.6.6 Spain Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.7 Denmark
9.2.7.1 Key Country Dynamics
9.2.7.2 Target Disease Prevalence
9.2.7.3 Competitive Scenario
9.2.7.4 Regulatory Framework
9.2.7.5 Reimbursement Scenario
9.2.7.6 Denmark Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.8 Sweden
9.2.8.1 Key Country Dynamics
9.2.8.2 Target Disease Prevalence
9.2.8.3 Competitive Scenario
9.2.8.4 Regulatory Framework
9.2.8.5 Reimbursement Scenario
9.2.8.6 Sweden Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.9 Norway
9.2.9.1 Key Country Dynamics
9.2.9.2 Target Disease Prevalence
9.2.9.3 Competitive Scenario
9.2.9.4 Regulatory Framework
9.2.9.5 Reimbursement Scenario
9.2.9.6 Norway Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.2.9.7 Rest of Europe Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.3 Asia Pacific
9.3.1 SWOT Analysis:
9.3.1.1 Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.3.2 Japan
9.3.2.1 Key Country Dynamics
9.3.2.2 Target Disease Prevalence
9.3.2.3 Competitive Scenario
9.3.2.4 Regulatory Framework
9.3.2.5 Reimbursement Scenario
9.3.2.6 Japan Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.3.3 China
9.3.3.1 Key Country Dynamics
9.3.3.2 Target Disease Prevalence
9.3.3.3 Competitive Scenario
9.3.3.4 Regulatory Framework
9.3.3.5 Reimbursement Scenario
9.3.3.6 China Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.3.4 India
9.3.4.1 Key Country Dynamics
9.3.4.2 Target Disease Prevalence
9.3.4.3 Competitive Scenario
9.3.4.4 Regulatory Framework
9.3.4.5 Reimbursement Scenario
9.3.4.6 India Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.3.5 Australia
9.3.5.1 Key Country Dynamics
9.3.5.2 Target Disease Prevalence
9.3.5.3 Competitive Scenario
9.3.5.4 Regulatory Framework & Reimbursement Scenario
9.3.5.5 Australia Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.3.6 Thailand
9.3.6.1 Key Country Dynamics
9.3.6.2 Target Disease Prevalence
9.3.6.3 Competitive Scenario
9.3.6.4 Regulatory Framework & Reimbursement Scenario
9.3.6.5 Thailand Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.3.7 South Korea
9.3.7.1 Key Country Dynamics
9.3.7.2 Target Disease Prevalence
9.3.7.3 Competitive Scenario
9.3.7.4 Regulatory Framework & Reimbursement Scenario
9.3.7.5 South Korea Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.3.7.6 Rest of Asia Pacific Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.4 Latin America
9.4.1 SWOT Analysis:
9.4.1.1 Latin America Generic Pharmaceutical market estimates and forecasts, 2018 – 2030 (USD Billion)
9.4.2 Brazil
9.4.2.1 Key Country Dynamics
9.4.2.2 Target Disease Prevalence
9.4.2.3 Competitive Scenario
9.4.2.4 Regulatory Framework
9.4.2.5 Reimbursement Scenario
9.4.2.6 Brazil Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.4.3 Mexico
9.4.3.1 Key Country Dynamics
9.4.3.2 Target Disease Prevalence
9.4.3.3 Competitive Scenario
9.4.3.4 Regulatory Framework
9.4.3.5 Reimbursement Scenario
9.4.3.6 Mexico Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.4.4 Argentina
9.4.4.1 Key Country Dynamics
9.4.4.2 Target Disease Prevalence
9.4.4.3 Competitive Scenario
9.4.4.4 Regulatory Framework
9.4.4.5 Reimbursement Scenario
9.4.4.6 Argentina Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.4.4.7 Rest of Latin America Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.5 Middle East & Africa (MEA)
9.5.1 SWOT Analysis:
9.5.1.1 Middle East & Africa Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.5.2 South Africa
9.5.2.1 Key Country Dynamics
9.5.2.2 Target Disease Prevalence
9.5.2.3 Competitive Scenario
9.5.2.4 Regulatory Framework
9.5.2.5 Reimbursement Scenario
9.5.2.6 South Africa Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.5.3 Saudi Arabia
9.5.3.1 Key Country Dynamics
9.5.3.2 Target Disease Prevalence
9.5.3.3 Competitive Scenario
9.5.3.4 Regulatory Framework
9.5.3.5 Reimbursement Scenario
9.5.3.6 Saudi Arabia Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.5.4 UAE
9.5.4.1 Key Country Dynamics
9.5.4.2 Target Disease Prevalence
9.5.4.3 Competitive Scenario
9.5.4.4 Regulatory Framework
9.5.4.5 Reimbursement Scenario
9.5.4.6 UAE Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.5.5 Kuwait
9.5.5.1 Key Country Dynamics
9.5.5.2 Target Disease Prevalence
9.5.5.3 Competitive Scenario
9.5.5.4 Regulatory Framework
9.5.5.5 Reimbursement Scenario
9.5.5.6 Kuwait Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
9.5.5.7 Rest of MEA Generic Pharmaceutical Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
Chapter 10 Generic Pharmaceuticals Market – Competitive Analysis
10.1 Recent Developments & Impact Analysis, by Key Market Participants
10.1.1 New Product Launch
10.1.2 Merger and Acquisition
10.1.3 Licensing Agreements
10.1.4 Conferences and Campaigns
10.2 Company Categorization
10.2.1 Innovators
10.2.2 Market Leaders
10.3 Vendor Landscape
10.3.1 List of key distributors and channel partners
10.3.2 Key customers
10.4 Public Companies
10.4.1 Key company market share analysis, 2022
10.4.2 Company market position analysis
10.4.3 Heat map analysis
10.4.4 Competitive Dashboard Analysis
10.4.4.1 Market Differentiators
10.5 Private Companies
10.5.1 List of key emerging companies
10.5.2 Regional Network Map
10.6 Company Profile
10.6.1 Teva Pharmaceutical Industries Ltd
10.6.1.1 Company overview
10.6.1.2 Financial performance
10.6.1.3 Product benchmarking
10.6.1.4 Strategic initiatives
10.6.2 Viatris Inc.)
10.6.2.1 Company overview
10.6.2.2 Financial performance
10.6.2.3 Product benchmarking
10.6.2.4 Strategic initiatives
10.6.3 Sun Pharmaceutical Industries Ltd.
10.6.3.1 Company overview
10.6.3.2 Financial performance
10.6.3.3 Product benchmarking
10.6.3.4 Strategic initiatives
10.6.4 LUPIN
10.6.4.1 Company overview
10.6.4.2 Financial performance
10.6.4.3 Product benchmarking
10.6.4.4 Strategic initiatives
10.6.5 Novartis AG
10.6.5.1 Company overview
10.6.5.2 Sandoz International GmbH
10.6.5.3 Financial performance
10.6.5.4 Product benchmarking
10.6.5.5 Strategic initiatives
10.6.6 Allergan
10.6.6.1 Company overview
10.6.6.2 Financial performance
10.6.6.3 Product benchmarking
10.6.6.4 Strategic initiatives
10.6.7 AstraZeneca
10.6.7.1 Company overview
10.6.7.2 Financial performance
10.6.7.3 Product benchmarking
10.6.7.4 Strategic initiatives
10.6.8 Sawai Pharmaceutical Co., Ltd.
10.6.8.1 Company overview
10.6.8.2 Financial performance
10.6.8.3 Product benchmarking
10.6.8.4 Strategic initiatives
10.6.9 Hikma Pharmaceuticals PLC
10.6.9.1 Company overview
10.6.9.2 Financial performance
10.6.9.3 Product benchmarking
10.6.9.4 Strategic initiatives
10.6.10 Dr. Reddy’s Laboratories Ltd.
10.6.10.1 Company overview
10.6.10.2 Financial performance
10.6.10.3 Product benchmarking
10.6.10.4 Strategic initiatives
10.6.11 Cipla Inc.
10.6.11.1 Company overview
10.6.11.2 Financial performance
10.6.11.3 Product benchmarking
10.6.11.4 Strategic initiatives
10.6.12 Sanofi
10.6.12.1 Company overview
10.6.12.2 Financial performance
10.6.12.3 Product benchmarking
10.6.12.4 Strategic initiatives
10.6.13 Aurobindo Pharma
10.6.13.1 Company overview
10.6.13.2 Financial performance
10.6.13.3 Product benchmarking
10.6.13.4 Strategic initiatives
10.6.14 Endo International plc
10.6.14.1 Company overview
10.6.14.2 Financial performance
10.6.14.3 Product benchmarking
10.6.14.4 Strategic initiatives

※본 조사보고서 [세계의 제네릭 의약품 시장 (2023~2030) : 단순 제네릭, 특수 제네릭, 바이오시밀러] (코드 : GRV23MR095) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 제네릭 의약품 시장 (2023~2030) : 단순 제네릭, 특수 제네릭, 바이오시밀러] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
[이하, 관련 보고서 소개]

  • 세계의 의약품 시장 2023-2030 : 생물제제 및 바이오시밀러 (대형 분자), 기존 의약품 (저분자 의약품)
    GRV24JNU037 / Grand View Research / 2023년 12월 / 글로벌 의약품 시장의 성장과 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 의약품 시장 규모는 2023년부터 2030년까지 연평균 6.12%의 성장률로 확대되어 2030년에는 2조 2,3632.5억 달러에 이를 것으로 예측됩니다. 의약품...1. 조사 방법 및 범위 2. 개요 3. 세계의 의약품 시장 변수, 동향, 범위 4. 세계의 의약품 시장 규모 : 분자 유형별 예측 및 동향 분석 5. 세계의 의약품 시장 규모 : 제품별 예측 및 동향 분석 6. 세계의 의약품 시장 규모 : 유형별 예측 및 동향 분석 7. 세계의...
  • 세계의 에리스로포이에틴 제제 시장 (2023~2030) : 생물 제제, 바이오시밀러
    GRV23MR091 / Grand View Research / 2023년 2월 / 미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 에리스로포이에틴 제제 시장 규모가 2023년부터 2030년 사이에 CAGR 1.5% 증가하여, 2030년에는 78억 달러에 달할 것으로 전망하고 있습니다. 본 조사 자료는 세계의...Erythropoietin Drugs Market Growth & Trends The global erythropoietin drugs market size is expected to reach USD 7.8 billion expanding at a CAGR of 1.5% from 2023 to 2030, according to a new report by Grand View Research, Inc., The slow growth can be attributed to the patent expiry of...
  • 세계의 첨단 치료제 CDMO 시장 (2023-2030) : 유전자 치료, 세포 요법, 조직 공학
    GRV23MA018 / Grand View Research / 2023년 1월 / 미국 Grand View Research (그랜드뷰리서치)는 세계의 첨단 치료제 CDMO 시장 규모가 2023년부터 2030년 사이에 연평균 18.8% 성장하여, 2030년에는 188억 달러에 달할 것으로 예측하고 있습니다. 본 조사 자료는 세계의 첨단 치료제...Advanced Therapy Medicinal Products CDMO Market Growth & Trends The global advanced therapy medicinal products CDMO market size is expected to reach USD 18.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.8% from 2023 to...
  • 글로벌 펩티드 약물 복합체 시장 (2023-2030) : 루테튬, 멜플루펜, ANG1005, BT1718, CBX-12, 기타 파이프 라인
    GRV23NOV280 / Grand View Research / 2023년 9월 / 글로벌 펩타이드 약물 복합체 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 펩타이드 약물 복합체 시장은 2030년까지 42억 1000만 달러에 달할 것으로 예상되며, 예측 기간 동안 28. 58%의...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 펩티드 약물 복합체 시장 : 유형별 예측 및 동향 분석 Chapter 5. 세계의 펩티드 약물 복합체 시장 : 제품별 예측 및 동향 분석 Chapter 6. 세계의 펩티드 약물 복합체 시장 : 지역별...
  • 세계의 네뷸라이저 시장 (2023~2030) : 제트, 메쉬, 초음파
    GRV23MA046 / Grand View Research / 2023년 1월 / 미국 Grand View Research (그랜드뷰리서치)는 세계의 네뷸라이저 시장 규모가 2023년부터 2030년 사이에 연평균 5.9% 성장하여, 2030년에는 17억 달러에 달할 것으로 전망하고 있습니다. 본 조사 자료는 세계의 네뷸라이저 시장을 조사 및...Nebulizer Market Growth & Trends The global nebulizer market size is expected to reach USD 1.70 billion by 2030, expanding at a CAGR of 5.9%, from 2023 to 2030, according to a new report by Grand View Research Inc., Rising incidence rate of chronic respiratory diseases, increasing demand for home...